- Home
- NKTX vs PROK Comparison
NKTX vs PROK Comparison
Compare NKTX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- PROK
- Stock Information
- Founded
- NKTX 2015
- PROK 2015
- Country
- NKTX United States
- PROK United States
- Employees
- NKTX N/A
- PROK N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NKTX Health Care
- PROK Health Care
- Exchange
- NKTX Nasdaq
- PROK Nasdaq
- Market Cap
- NKTX 123.5M
- PROK 129.5M
- IPO Year
- NKTX 2020
- PROK N/A
- Fundamental
- Price
- NKTX $1.77
- PROK $0.71
- Analyst Decision
- NKTX Strong Buy
- PROK Buy
- Analyst Count
- NKTX 6
- PROK 3
- Target Price
- NKTX $14.40
- PROK $4.50
- AVG Volume (30 Days)
- NKTX 422.2K
- PROK 606.0K
- Earning Date
- NKTX 08-12-2025
- PROK 08-08-2025
- Dividend Yield
- NKTX N/A
- PROK N/A
- EPS Growth
- NKTX N/A
- PROK N/A
- EPS
- NKTX N/A
- PROK N/A
- Revenue
- NKTX N/A
- PROK $306,000.00
- Revenue This Year
- NKTX N/A
- PROK $54.34
- Revenue Next Year
- NKTX N/A
- PROK N/A
- P/E Ratio
- NKTX N/A
- PROK N/A
- Revenue Growth
- NKTX N/A
- PROK N/A
- 52 Week Low
- NKTX $1.31
- PROK $0.46
- 52 Week High
- NKTX $8.23
- PROK $2.75
- Technical
- Relative Strength Index (RSI)
- NKTX 46.34
- PROK 44.48
- Support Level
- NKTX $1.76
- PROK $0.69
- Resistance Level
- NKTX $2.08
- PROK $1.02
- Average True Range (ATR)
- NKTX 0.11
- PROK 0.11
- MACD
- NKTX -0.00
- PROK -0.01
- Stochastic Oscillator
- NKTX 25.00
- PROK 13.58
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.